Pfizer Pipeline. February 28, 2013

Transcription

1 Pfizer Pipeline February 28, 2013

2 Disclaimer As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from 3 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of February 28, Visit Pfizer.com/pipeline, Pfizer s online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world. 2

3 Table of Contents Pfizer Pipeline Snapshot 4 Cardiovascular & Metabolic Diseases 5 Inflammation & Immunology 6 Neuroscience & Pain 7 Oncology 8 Vaccines 9 Other Areas of Focus 10 Projects Discontinued Since Last Update 11 3

4 Pfizer Pipeline Snapshot Discovery Projects 9 programs advanced or are new Pfizer Pipeline Snapshot as of February 28, In Reg Total 78 Pipeline represents progress of R&D programs as of February 28, 2013 Included are 61 NMEs, 15 additional indications, plus 2 biosimilars 4 projects discontinued since last update Recent Approval - Eliquis for Prevention of Stroke and Systemic Embolism in patients with Nonvalvular Atrial Fibrillation (U.S./EU) Discovery Projects 3 programs advanced or are new Pfizer Pipeline Snapshot as of November 8, In Reg Total 78 Pipeline represents progress of R&D programs as of November 8, 2012 Included are 59 NMEs, 17 additional indications, plus 2 biosimilars 8 projects discontinued since last update Recent Approvals - Xeljanz (tofacitinib) for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate (U.S.) - Xalkori for treatment of previously treated ALKpositive advanced non-small cell lung cancer (EU) - Bosulif (bosutinib) for treatment of previously treated chronic myelogenous leukemia (U.S.) - Inlyta (axitinib) for treatment of advanced renal cell carcinoma after failure of prior systemic treatment (EU) 4

5 Pfizer Pipeline February 28, 2013 Therapeutic Area Cardiovascular and Metabolic Diseases Compound Name Mechanism of Action ( 3 through regulatory approval) Eliquis (apixaban) Factor Xa Inhibitor Venous Thromboembolism Prevention (U.S.) 3 Eliquis (apixaban) Factor Xa Inhibitor Venous Thromboembolism Treatment 3 PF Diabetes Mellitus-Type 2 2 RN316 (PF ) Hypercholesterolemia (Biologic) 2 PF Diabetes Mellitus-Type 2 2 PF Diabetic Nephropathy 2 PF Diabetic Nephropathy 2 CVX 096 (PF ) Diabetes Mellitus-Type 2 (Biologic) 1 PF Diabetes Mellitus-Type 2 (Biologic) 1 PF Diabetes Mellitus-Type 2 1 RN317 (PF ) Hypercholesterolemia (Biologic) 1 PF Acute Coronary Syndrome 1 PF Diabetes Mellitus-Type 1 (Biologic) 1 New or 5

6 Pfizer Pipeline February 28, 2013 (cont d) Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) tofacitinib JAK Inhibitor Rheumatoid Arthritis (EU) Registration Xeljanz (tofacitinib) JAK Inhibitor Psoriasis (Oral) 3 Xeljanz (tofacitinib) JAK Inhibitor Ulcerative Colitis 3 PF Rheumatoid Arthritis 2 PF Ulcerative Colitis (Biologic) 2 anrukinzumab (IMA-638) Ulcerative Colitis (Biologic) 2 PF Crohn s Disease, Ulcerative Colitis (Biologic) 2 Inflammation and Immunology PF Crohn s Disease, Lupus, *Rheumatoid Arthritis (Biologic) 2 PH Chronic Obstructive Pulmonary Disease 2 PF (EXC 001) Dermal Scarring 2 Xeljanz (tofacitinib) Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis (Topical), Crohn s Disease 2 Dekavil Rheumatoid Arthritis (Biologic) 1 PF Chronic Obstructive Pulmonary Disease 1 PD Lupus (Biologic) 1 PF Rheumatoid Arthritis (Biosimilar) 1 New or Biosimilar * Note: Additional indications in 1 6

7 Pfizer Pipeline February 28, 2013 (cont d) Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) Neuroscience & Pain tafamidis meglumine Transthyretin (TTR) Dissociation Inhibitor Transthyretin familial amyloid polyneuropathy (U.S.) Registration Celebrex COX-2 Chronic Pain (U.S.) Registration Remoxy ALO-02 Oxycodonenaltrexone core Mu-type opioid receptor (MOR-1) Agonist Mu-type opioid receptor (MOR-1) Agonist Moderate to Severe Pain (U.S.) Registration Moderate to Severe Pain 3 Lyrica Alpha-2 Delta Ligand Peripheral Neuropathic Pain 3 Lyrica Alpha-2DeltaLigand CR (once a day dosing) 3 tanezumab Nerve Growth Factor Inhibitor OA Signs and Symptoms (Biologic) (on clinical hold) 3 PF (SAM- 760) Alzheimer s Disease 2 PF Stroke Recovery 2 tanezumab Cancer Pain (Biologic) 2 PF Chronic Pain 1 PF (AAB-003) Alzheimer s Disease (Biologic) 1 PF Schizophrenia, Sensorineural Hearing Loss 1 PF Chronic Pain 1 PF Acute and Chronic Pain 1 New or 7

8 Pfizer Pipeline February 28, 2013 (cont d) Therapeutic Area Oncology Compound Name bosutinib dacomitinib (PF ) Mechanism of Action ( 3 through regulatory approval) Abl and src-family kinase inhibitor pan-her Inhibitor Treatment of Previously Treated Chronic Myelogenous Leukemia (EU) Previously Treated Advanced Non-Small Cell Lung Cancer Registration 3 Xalkori (crizotinib) c-met-alk Inhibitor ALK-Positive 1st and 2nd Line (supports potential full approval in the U.S.) Non- Small Cell Lung Cancer, *Cancer 3 Inlyta (axitinib) VEGF Tyrosine Kinase Inhibitor Renal Cell Carcinoma Adjuvant (Asia only) 3 Sutent Multiple Tyrosine Kinase Inhibitor Renal Cell Carcinoma Adjuvant 3 palbociclib (PD ) CDK 4,6 Kinase Inhibitor 1 st Line Advanced Breast Cancer, *Cancer 3 inotuzumab ozogamicin i Aggressive Non-Hodgkin s Lymphoma (Biologic) 3 inotuzumab ozogamicin Acute Lymphoblastic Leukemia (Biologic) 3 Inlyta (axitinib) Liver Cancer 2 dacomitinib (PF ) Cancer 2 PF Endometrial Cancer, *Cancer 2 CVX 060 (PF ) Renal Cell Carcinoma, *Cancer (Biologic) 1 PF Cancer 1 PF Cancer (Biologic) 1 PD Cancer (in combination with PF ) 1 New or * Note: Additional indications in 1 8

9 Pfizer Pipeline February 28, 2013 (cont d) Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) PF Cancer (Biologic) 1 Oncology (cont d) Vaccines PF Cancer (Biologic) 1 PF Metastatic Breast Cancer (Biosimilar) 1 PF Acute Myelocytic Leukemia 1 MnB rlp2086 (PF ) Adolescent and Young Adult Meningitis B 3 ACC-001 (PF ) Alzheimer s Disease 2 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) Staph Aureus 2 (PF ) PF Smoking Cessation 1 PF Clostridium Difficile Colitis 1 PF Asthma 1 New or Biosimilar 9

10 Pfizer Pipeline February 28, 2013 (cont d) Therapeutic Area Compound Name Mechanism of Action ( 3 through regulatory approval) Other Areas of Focus bazedoxifeneconjugated estrogens Tissue Selective Estrogen Complex Menopausal Vasomotor Symptoms ( U.S.) / (EU) Registration Viviant Selective Estrogen Receptor Modulator Osteoporosis Treatment and Prevention (U.S.) Registration Zithromax/chloroquine 5-OS Ribosome Inhibitor Malaria 3 bosutinib PF (GMI-1070) Autosomal Dominant Polycystic Kidney Disease Vaso-occlusive crisis associated with Sickle Cell Disease 2 2 PNU Tuberculosis 2 RN6G (PF ) Age-Related Macular Degeneration (Biologic) 2 PF Hemophilia (Biologic) 1 PF Muscular Dystrophies (Biologic) 1 PF Spinal Muscular Atrophy 1 New or 10

11 Projects Discontinued from Development since November 8, 2012 Compound Name Mechanism of Action ( 3 through regulatory approval) PF (filibuvir) Hepatitis C Virus 2 PF Schizophrenia 2 tofacitinib (CP ) Transplant Rejection 2 PF Schizophrenia 1 New or 11